Patents by Inventor Bradford A. Jameson
Bradford A. Jameson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100075402Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-? and TPO, linked to a subunit of a natural heterodimeric scaffold. Each coexpressed sequence contains a corresponding subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: ApplicationFiled: September 26, 2007Publication date: March 25, 2010Applicant: LABORATOIRES SERONO SAInventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Publication number: 20090240039Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-? and TPO, linked to a subunit of a natural heterodimeric scaffold. Each coexpressed sequence contains a corresponding subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: ApplicationFiled: October 30, 2007Publication date: September 24, 2009Inventors: Robert K. CAMPBELL, Bradford A. Jameson, Scott C. Chappel
-
Patent number: 7291339Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-? and TPO, linked to ? subunit of a natural heterodimeric scaffold. Each coexpressed sequence contains a corresponding subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: GrantFiled: December 1, 2003Date of Patent: November 6, 2007Assignee: Laboratoires Serono SAInventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Publication number: 20060183757Abstract: The present invention relates to the discovery that signaling via a serotonin type 1B, 2, 4 and 6 receptor is important in T cell activation such that inhibiting such signaling, such as by using fluphenazine, can be used to modulate the immune response, cell proliferation, and apoptosis, among other cell processes. This immunomodulation is useful for the treatment of immune diseases or conditions, and for the development of potential therapeutics for such diseases or conditions. It has been further discovered that, in cells proceeding through the cell cycle process, inhibition of serotonin signaling inhibits the process and induces apoptosis and morphological changes to a cell. These effects of inhibiting serotonergic signaling can be useful for effecting selective cell killing and for identifying compounds that inhibit the signaling. Additionally, methods for the use, identification and production of an inhibitor that does not substantially cross the blood-brain barrier are also provided.Type: ApplicationFiled: December 16, 2004Publication date: August 17, 2006Inventors: Bradford Jameson, Anna Tretiakova, Harold Davidson
-
Publication number: 20060135415Abstract: The present invention relates to the discovery that signaling via a serotonin type 1B, 2, 4 and 6 receptor is important in T cell activation such that inhibiting such signaling, such as by using fluphenazine, can be used to modulate the immune response, cell proliferation, and apoptosis, among other cell processes. This immunomodulation is useful for the treatment of immune diseases or conditions, and for the development of potential therapeutics for such diseases or conditions. It has been further discovered that, in cells proceeding through the cell cycle process, inhibition of serotonin signaling inhibits the process and induces apoptosis and morphological changes to a cell. These effects of inhibiting serotonergic signaling can be useful for effecting selective cell killing and for identifying compounds that inhibit the signaling. Additionally, methods for the use, identification and production of an inhibitor that does not substantially cross the blood-brain barrier are also provided.Type: ApplicationFiled: December 2, 2005Publication date: June 22, 2006Inventors: Bradford Jameson, Anna Tretiakova, Harold Davidson
-
Publication number: 20060039903Abstract: The present invention relates to the discovery that signaling via a serotonin type 1B, 2, 4 and 6 receptor is important in T cell activation such that inhibiting such signaling can be used to modulate the immune response. This immunomodulation is useful for the treatment of immune diseases or conditions, and for the development of potential therapeutics for such diseases or conditions. It has been further discovered that, in cells proceeding through the cell cycle process, inhibition of serotonin signaling inhibits the process and induces apoptosis and morphological changes to a cell. These effects of inhibiting serotonergic signaling can be useful for effecting selective cell killing and for identifying compounds that inhibit the signaling.Type: ApplicationFiled: August 4, 2005Publication date: February 23, 2006Inventors: Bradford Jameson, Anna Tretiakova, Ross Albert, Harold Davidson
-
Publication number: 20060003996Abstract: The present invention includes the treatment of psoriasis in a human comprising the intralesional administration of a phenothiazine, preferably fluphenazine, to a psoriatic plaque in the patient.Type: ApplicationFiled: June 17, 2005Publication date: January 5, 2006Inventors: Stephen Roth, Robert More, Bradford Jameson
-
Patent number: 6979447Abstract: The present invention relates to the discovery that signaling via a serotonin type 1B, 2, 4 and 6 receptor is important in T cell activation such that inhibiting such signaling can be used to modulate the immune response. This immunomodulation is useful for the treatment of immune diseases or conditions, and for the development of potential therapeutics for such diseases or conditions. It has been further discovered that, in cells proceeding through the cell cycle process, inhibition of serotonin signaling inhibits the process and induces apoptosis and morphological changes to a cell. These effects of inhibiting serotonergic signaling can be useful for effecting selective cell killing and for identifying compounds that inhibit the signaling.Type: GrantFiled: March 29, 2002Date of Patent: December 27, 2005Assignee: Philadelphia Health and Education CorporationInventors: Bradford A. Jameson, Anna A. Tretiakova, Ross Albert, Harold Carter Davidson
-
Publication number: 20050202467Abstract: The present invention relates to a novel spliced 5-HT1A receptor and nucleic acids encoding the same and the polypeptides encoded thereby.Type: ApplicationFiled: December 20, 2004Publication date: September 15, 2005Inventors: Bradford Jameson, Anna Tretiakova, Mark Haynes
-
Publication number: 20040230034Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&bgr; and TPO, linked to &agr; subunit of a natural heterodimeric scaffold. Each coexpressed sequence contains a corresponding subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: ApplicationFiled: December 1, 2003Publication date: November 18, 2004Applicant: Applied Research Systems ARS Holding N.V.Inventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Patent number: 6663867Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&bgr; and TPO, linked to a subunit of a heterodimeric proteinaceous hormone, such as hCG. Each coexpressed sequence contains a corresponding hormone subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: GrantFiled: January 9, 2001Date of Patent: December 16, 2003Assignee: Applied Research Systems ARS Holding N.V.Inventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Publication number: 20030100570Abstract: The present invention relates to the discovery that signaling via a serotonin type 1B, 2, 4 and 6 receptor is important in T cell activation such that inhibiting such signaling can be used to modulate the immune response. This immunomodulation is useful for the treatment of immune diseases or conditions, and for the development of potential therapeutics for such diseases or conditions. It has been further discovered that, in cells proceeding through the cell cycle process, inhibition of serotonin signaling inhibits the process and induces apoptosis and morphological changes to a cell. These effects of inhibiting serotonergic signaling can be useful for effecting selective cell killing and for identifying compounds that inhibit the signaling.Type: ApplicationFiled: March 29, 2002Publication date: May 29, 2003Inventors: Bradford A. Jameson, Anna A. Tretiakova, Ross Albert, Harold Carter Davidson
-
Publication number: 20010014333Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&bgr; and TP0, linked to a subunit of a heterodimeric proteinaceous hormone, such as hCG. Each coexpressed sequence contains a corresponding hormone subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: ApplicationFiled: January 9, 2001Publication date: August 16, 2001Applicant: Applied Research Systems ARS Holding N.V.Inventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Patent number: 6194177Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&bgr;and TPO, linked to a subunit of a heterodimeric proteinaceous hormone, such as hCG. Each coexpressed sequence contains a corresponding hormone subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: GrantFiled: August 14, 1997Date of Patent: February 27, 2001Assignee: Applied Research Systems ARS Holding N.V.Inventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Patent number: 6193972Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&bgr; and TPO, linked to a subunit of a heterodimeric proteinaceous hormone, such as hCG. Each coexpressed sequence contains a corresponding hormone subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: GrantFiled: February 20, 1997Date of Patent: February 27, 2001Assignee: Applied Research Systems ARS Holding N.V.Inventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Patent number: 6180600Abstract: Compounds that inhibit CD8 mediated T cell activation and that have a molecular surface that corresponds to the molecular surface of human CD8 at amino acids 38-46 and/or 53-56 and/or 60-67 and pharmaceutical compositions comprising such compounds are disclosed. Methods of inhibiting activation of a human T cell are disclosed. The methods comprise contacting a T cell with a compound that inhibits CD8 mediated T cell activation and that has a molecular surface that corresponds to the molecular surface of human CD8 at amino acids 38-46 and/or 53-56 and/or 60-67. Methods of treating an individual suspected of suffering from or susceptible to graft versus host disease and/or organ rejection are disclosed. The methods comprise administering an effective amount of a compound that inhibits CD8 mediated T cell activation and that has a molecular surface that corresponds to the molecular surface of human CD8 at amino acids 34-46 and/or 53-56 and/or 60-67.Type: GrantFiled: November 26, 1997Date of Patent: January 30, 2001Assignee: Thomas Jefferson UniversityInventors: Bradford A. Jameson, Swati Choksi, Robert Korngold, Ziwei Huang
-
Patent number: 6107273Abstract: TNF.alpha. antagonist compounds and methods of using the same are disclosed. The compounds comprise a molecular surface that is substantially similar to at least one molecular surface of human TNF.alpha.. The compounds bind to TNF receptors but do not produce the same biological effect as that which occurs when TNF.alpha. binds to a TNF receptor. Methods of inhibiting tumor necrosis factor activity are disclosed. The methods comprise the step of contacting tumor necrosis factor alpha with a TNF.alpha. antagonist. Methods of treating individuals suspected of suffering from or being susceptible to a disease or disorder mediated by tumor necrosis factor-alpha activity are disclosed. The methods comprise the step of administering to said individual a therapeutically effective amount of a TNF.alpha. antagonist.Type: GrantFiled: January 24, 1995Date of Patent: August 22, 2000Assignee: Thomas Jefferson UniversityInventors: Bradford A. Jameson, Mariadele Noe
-
Patent number: 5962634Abstract: The present invention relates to methods for modulating interaction between IgE and Fc.epsilon.R1. The present invention also relates to compounds that modulate IgE binding to Fc.epsilon.R1.Type: GrantFiled: April 30, 1997Date of Patent: October 5, 1999Assignees: Thomas Jefferson University, King's CollegeInventors: Bradford A. Jameson, Brian J. Sutton, James M. McDonnell, Hannah J. Gould, Robert Korngold, Andrew J. Beavil
-
Patent number: 5958882Abstract: Compounds which display a surface similar to the surface presented by one of five distinct lateral domains of CD4 are disclosed. Methods of treating individuals suspected of suffering from or susceptible to conditions characterized by an undesired immune response comprising administering to the individual at least one compound which mimics a portion of the lateral surface of the CD4 glycoprotein are disclosed.Type: GrantFiled: October 11, 1996Date of Patent: September 28, 1999Assignee: Thomas Jefferson UniversityInventors: Bradford A. Jameson, James M. McDonnell, Robert Korngold
-
Patent number: 5770693Abstract: Synthetic peptide analogs of human kininogen are provided which are conformationally restricted by means of intramolecular bonding. The peptides mimic the biological activity of human kininogen by inhibiting the activity of the biologically significant protease, calpain. The peptides are designed by means of an equilibrium conformational model of the kininogen heavy chain.Type: GrantFiled: June 6, 1995Date of Patent: June 23, 1998Assignee: Temple University-Of The Commonwealth System of Higher EducationInventors: Robert W. Colman, Harlan N. Bradford, Bradford A. Jameson